Navigation Links
Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
Date:4/15/2008

Companies Also Sign Manufacturing and Distribution Agreement

GURGAON, India and PRINCETON, N.J., April 15 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it has reached several agreements with AstraZeneca. Two of these agreements concern Esomeprazole magnesium capsules. The third agreement pertains to Omeprazole 40mg tablets, and the fourth agreement pertains to Felodipine ER capsules. All of the agreements are specific to the U.S. market.

The agreement settles the patent infringement litigation filed by AstraZeneca following Ranbaxy's submission to the United States Food & Drug Administration of an Abbreviated New Drug Application for a generic version of Esomeprazole magnesium. Under the settlement agreement, Ranbaxy concedes that all six patents asserted by AstraZeneca in the patent litigation are valid and enforceable.

The settlement agreement will allow Ranbaxy to commence exclusive sales of a generic version of Nexium under a license from AstraZeneca on May 27, 2014. During the 180-day period following the date, RPI will distribute the only generic Esomeprazole magnesium product in the US market.

Ranbaxy has filed a Consent Judgment with the U.S. District Court for the District of New Jersey reflecting the terms of the settlement agreement. With the Court now having entered the Consent Judgment, the settlement agreement is final, and the patent infringement litigation against Ranbaxy has been dismissed.

Merck & Co., Inc., through KBI Inc. and KBI-E and under the terms of Merck's restructured partnership with AstraZeneca announced in 1998, has also entered into the settlement agreement.

"We are pleased with the agreement which will provide certainty as to the launch of a generic formulation of Esomeprazole magnesium in the US market," according to Malvinder M. Singh, CEO and Managing Director of Ranbaxy Laboratories Ltd.
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
2. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
3. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
4. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
5. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
6. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
8. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
9. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
10. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
11. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 30, 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A ... Summary:Three-months ended September 30, , Nine-months ended ... 2014 , 2013 , 2014 ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring Dr. ... in the Regulatory Biology Laboratory at the Salk Institute, studies ... an “off switch” for drug resistance in cancer. , Learn ... is making a global impact in the fight against cancer. ... Cheryl K. Goodman, CEO of Social Global Mobile LLC, for ...
(Date:11/18/2014)... 18, 2014 Array Architects is proud ... expertise to the nation's hospitals and health systems. It ... those dedicating their careers to the advancement of both ... in her respective field, Laura Silvoy has been chosen ... 2014 Winter Simulation Conference. , Laura will present ...
Breaking Biology Technology:Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2
... Fourth Quarter Highlights:, -- Record revenues of $82.0 million, up 22% from the prior year,s fourth ... quarter ... $0.23, a 130% increase over last year,s ... of $24.3 million, revolving debt facility paid off, -- Launch of four new food and beverage products and ...
... WILMINGTON, N.C., Dec. 12 PPD, Inc. ... M.D., as director,of strategic development, to lead the ... Dr. Mathew will provide strategic leadership for PPD,s ... project management,and patient recruitment for key therapeutic areas. ...
... 12 Beckman Coulter,Inc. (NYSE: BEC ), ... complex biomedical testing, announced today that Susan R.,Nowakowski, ... Services, Inc. (NYSE: AHS ) has been ... effective December 10., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ...
Cached Biology Technology:Martek Announces Fourth Quarter and FY 2007 Financial Results 2Martek Announces Fourth Quarter and FY 2007 Financial Results 3Martek Announces Fourth Quarter and FY 2007 Financial Results 4Martek Announces Fourth Quarter and FY 2007 Financial Results 5Martek Announces Fourth Quarter and FY 2007 Financial Results 6Martek Announces Fourth Quarter and FY 2007 Financial Results 7Martek Announces Fourth Quarter and FY 2007 Financial Results 8Martek Announces Fourth Quarter and FY 2007 Financial Results 9Martek Announces Fourth Quarter and FY 2007 Financial Results 10Martek Announces Fourth Quarter and FY 2007 Financial Results 11Martek Announces Fourth Quarter and FY 2007 Financial Results 12Martek Announces Fourth Quarter and FY 2007 Financial Results 13Martek Announces Fourth Quarter and FY 2007 Financial Results 14Martek Announces Fourth Quarter and FY 2007 Financial Results 15Mathew to Lead PPD Drug Development Operations and Expansion in India 2Mathew to Lead PPD Drug Development Operations and Expansion in India 3Beckman Coulter Elects AMN Healthcare Executive to Board of Directors 2
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
(Date:11/2/2014)... to put a flashlight up to our palms to ... in St. Louis engineers are using a similar idea ... imaging of cancerous tissues and to develop potential treatments. ... Distinguished Professor of Biomedical Engineering at the School of ... technology that allows researchers to better focus light in ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... KAN. -- It,s a cloak that surpasses all others: ... change the way bacteria and other cells are imaged. ... Kansas State University, and his research team are wrapping ... bacteria under electron microscopes. Berry,s method creates a carbon ...
... 15In the latest twist on optical knots, New York ... create extended and knotted optical traps in three dimensions. ... Optical Society,s (OSA) open-access journal Optics Express , ... intensity traces out a knotted trajectory in space, for ...
... variety of plant seedlings suffer most from competition when planted ... relatives in field soils, researchers from Case Western Reserve University ... when seeds of the same species are buried among relatives ... and grow better early in life in close relatives, habitats ...
Cached Biology News:All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 2All wrapped up: K-State researcher's graphene cloak protects bacteria, leading to better images 3Tying the knot with computer-generated holograms: Winding optical path moves matter 2Tying the knot with computer-generated holograms: Winding optical path moves matter 3Seedlings thrive with distant relatives, seeds with close family 2
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
Biology Products: